{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"9.6","value":"20.8"}]}],"title":"Baseline (n=19)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"9.4","value":"16.7"}]}],"title":"Week 4 (n=18)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"5.6","value":"9.9"}]}],"title":"Week 9 (n=15)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"8.5","value":"13.2"}]}],"title":"Week 13 (n=15)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"19"}],"units":"Participants"}],"description":"Functional Assessment of Cancer Treatment - Gynecologic Oncology Group Neurotoxicity Scale (FACT/GOG-Ntx) Version 4 used to assess efficacy of acupuncture for treatment-induced peripheral neuropathy among multiple myeloma and/or lymphoma patients. Severity of neuropathy measured by FACT-GOG-Ntx total score assessment where 11-item questionnaire 5 point rating scale (0=\"not at all\" and 4=equals \"very much\"). FACT/GOG-Ntx Total Score ranges from 0 (best possible outcome) to 44 (worst possible outcome).","dispersionType":"Standard Deviation","groups":[{"description":"Three (3) acupuncture sessions per week for 4 weeks (Weeks 1-4), 1 week off (Week 5), then 2 per week for 4 more weeks (Weeks 6-10), total of 20 sessions. Each session lasts 20-30 minutes.","id":"OG000","title":"Acupuncture"}],"paramType":"MEAN","populationDescription":"Participants were excluded from primary outcome if did not complete follow up assessments.","reportingStatus":"POSTED","timeFrame":"Baseline to Week 13. Assessments at baseline, once per week during the two treatment phases of the study, and one month (week 13) after the last acupuncture treatment.","title":"Mean Neuropathy Severity Score (FACT-GOG-Ntx Total Score Assessment)","type":"PRIMARY","unitOfMeasure":"units on a scale"}